查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1195707

血管成形術球囊市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Angioplasty Balloons Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

血管成形術球囊市場預計將在 2021 年達到約 26.3925 億美元，在 2027 年達到 33.4312 億美元，預測期內（2022-2027 年）的複合年增長率約為 3.5%。

2020 年初爆發的 COVID-19，加上對合併症患者的嚴重影響，由於封鎖規定，預計將對研究市場產生重大影響。 由於大流行，心臟治療的延遲和取消影響了市場。 例如，2020 年 11 月發表的一項題為“COVID-19 大流行對 STEMI 患者機械再灌注的影響”的研究發現，直接經皮冠狀動脈介入治療 (PPCI) 手術減少了 19%，尤其是在高血壓患者中。 COVID-19 大流行也對 ST 段抬高型心肌梗死 (STEMI) 患者的治療產生了重大影響。 然而，根據約翰霍普金斯醫學院 2022 年 4 月發表的一篇論文《COVID-19 之後的心臟問題》，冠狀病毒可以直接感染和傷害心臟的肌肉組織，也可以損傷靜脈和動脈。心臟內表面可能會感染冠狀病毒，導致血栓、血管損傷、周圍血管發炎，以及流向心臟和其他器官的血流受損。 因此，預計 COVID-19 將對心血管系統產生非常大的影響，這可能會在預測期內影響市場。

隨著心血管疾病負擔的增加和對微創手術的偏好，血管成形術球囊正在成為冠狀動脈和外周動脈疾病患者的首選治療方法。 心血管疾病在世界範圍內以驚人的速度增長，需要具有高成功率的精確療法。 例如，根據歐洲心臟網2021年公佈的數據，歐盟有超過6000萬人患有心血管疾病，每年新增確診病例近1300萬。 預計上述因素將在預測期內推動市場增長。

生活方式疾病患病率上升和老年人口增加等因素正在推動血管成形術球囊市場的增長。 例如，根據世界衛生組織 (WHO) 2021 年 10 月更新，估計 60 歲及以上人口將從 2020 年的 10 億增加到 21 億。 因此，隨著老年人口的增加，慢性病，尤其是心血管疾病的患病率預計也會增加，從而導致住院和手術。 此外，市場參與者越來越多地推出創新產品以滿足不斷增長的需求也有望推動市場增長。 例如，2021年3月，美敦力在歐洲安妮地區推出了用於經皮腔內血管成形術的“變色龍”球囊導管。 然而，與血管成形術相關的高成本和術後並發症預計會阻礙市場增長。

血管成形術球囊的市場趨勢

預計在預測期內，醫院部分將主導血管成形術球囊市場

預計醫院部分將佔整個血管成形術球囊市場的主要份額。 該細分市場的主導因素是先進的醫療基礎設施、熟練勞動力的增加和負擔能力。 此外，患有動脈硬化和心力衰竭等生活方式相關疾病的老年人口顯著增加，預計將增加患者數量並提高醫院利潤。

此外，微創手術與傳統手術相比的幾個優點是微創球囊血管成形術，如減少手術疼痛、損傷、疤痕、住院、準確率高、恢復時間快等。鼓勵許多患者選擇 根據美國心髒病學會 2020 年報告的數據，美國每年大約進行 120 萬例血管成形術手術。 此外，與專科診所相比，醫院的便利性和可負擔性預計將吸引更多患者。

但是，由於當前 COVID-19 的情況，目前醫院居民的行動受到限制。 除了緊急情況，人們希望避免手術或診斷程序以降低感染 COVID-19 的風險。 醫院還將工作人員從心臟部門轉移到其他需要的部門，例如 ED 和重症監護病房 (ICU)。 預計所有這些因素都會影響市場的增長。 然而，這種增長放緩是暫時的，從長遠來看，市場有望顯著增長。

下圖顯示，由於生活方式的改變和肥胖的增加，心血管疾病負擔在北美等發達地區持續增加。 預計此類疾病的激增將推動血管成形術球囊市場的需求。

預計在預測期內北美將佔據血管成形術球囊市場的重要份額

北美佔血管成形術球囊市場的最大收入份額。 主要行業參與者的存在、醫療保健支出的增加、經皮冠狀動脈介入治療的增加等是該地區市場的主要驅動力。 根據疾病控制和預防中心 (CDC) 的數據，到 2022 年，美國每年將有大約 659,000 人死於心髒病，佔死亡人數的四分之一。 因此，對先進醫療設備作為推動研究市場的主要因素的更好治療存在很高的需求。

美國監管機構對產品批准的增加預計也將推動市場增長。 2020年11月，InfinityAngioplasty Balloon Co.推出了名為Infinity Angioplasty Balloon Catheter的革命性血管成形術球囊平台，並完成了首次人體臨床試驗。 該設備於 2020 年 6 月獲得美國食品和藥物管理局批准，用於治療外周動脈疾病的 PTA，包括髂動脈、股動脈、膕動脈和膝下動脈，以及動靜脈透析瘺的治療。 這些新興市場的發展有望進一步增強這些市場的產品陣容，並為該地區的市場提供有利可圖的增長機會。

血管成形術球囊市場競爭對手分析

血管成形術球囊市場是分散的，有許多知名企業。 從市場份額的角度來看，目前幾家大型企業佔據了市場主導地位。 目前主導市場的公司包括 Abbott laboratories、Angiodynamic、Becton Dickinson、Biotronik、Boston Scientific Corporation、Braun Melsungen AG、Cook Medical、Cordis、Endocor GmbH、Infinity Angioblast balloon、Johnson & Johnson、Koninklijke Philips N.V.、Medtronic plc.、Merit Medical System, Inc、Oscor Inc、Terumo Corporation 等等。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 增加心血管疾病的負擔
    • 對微創手術和技術進步的偏好上升
  • 市場製約因素
    • 與手術相關的高成本
    • 與血管成形術相關的並發症
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品類型
    • 普通氣球
    • 切割/刻劃氣球
    • 藥物洗脫球囊
  • 通過申請
    • 冠狀動脈成形術
    • 外周血管成形術
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • AngioDynamics
    • Becton Dickinson
    • BIOTRONIK
    • Boston Scientific Corporation
    • Braun Melsungen AG
    • Cook Medical
    • Cordis（Cardinal Health）
    • Endocor GmbH
    • INFINITY Angioplasty Balloon
    • Johnson & Johnson
    • Koninklijke Philips N.V.
    • Medtronic Plc
    • Merit Medical Systems, Inc.
    • Oscor Inc.
    • Terumo Corporation

第7章 市場機會與今後動向

簡介目錄
Product Code: 64158

The angioplasty balloons market was valued at about USD 2639.25 million in 2021 and is expected to reach USD 3343.12 million in 2027, registering a CAGR of nearly 3.5% during the forecast period (2022-2027).

The emergence of COVID-19 in early 2020 was expected to have a significant impact on the studied market owing to the lockdown restrictions coupled with the severe impact of COVID-19 on people with comorbidities. Due to the pandemic, delay or cancellation in cardiology procedures was observed which affected the market. For instance, according to the research study published in November 2020, titled "Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI", there was a 19% decrease in primary percutaneous coronary intervention (PPCI) procedures, particularly among patients with hypertension. Also, the COVID-19 pandemic had a significant impact on the care of patients with ST-segment elevation myocardial infarction (STEMI). However, according to an article published in April 2022 by John Hopkins Medicine, titled "Heart Problems after COVID-19", the coronavirus may directly infect and harm the heart's muscular tissue, and also, the inner surfaces of veins and arteries can become infected by the coronavirus, which can then lead to blood clots, blood vessel damage, and inflammation of surrounding blood vessels, all of which can impair blood flow to the heart and other organs. Hence, COVID-19 is expected to have a very significant impact on the cardiovascular systems which may affect the market over the forecast period.

With the increasing burden of cardiovascular diseases and the preference for minimally invasive surgery, balloon angioplasty has become the method of choice to treat patients suffering from coronary and peripheral artery diseases. Cardiovascular diseases worldwide are increasing at an enormous rate, which calls for precise treatment alternatives with high success rates. For instance, the data published by the European Heart network in 2021 reported that in the European Union, more than 60 million people live with cardiovascular disease, and nearly 13 million new cases of cardiovascular diseases are diagnosed yearly. The above-mentioned factors are expected to drive the growth of the market during the forecast period.

Factors such as the rising prevalence of lifestyle-related disorders and increasing geriatric populations are fueling the growth of the angioplasty balloons market. For instance, according to the World Health Organization (WHO) October 2021 update, the estimated population of people aged 60 years or more is expected to increase from 1 billion in 2020 to 2.1 billion. Thus, with an increase in the geriatric population, the prevalence of chronic diseases, especially cardiovascular disease, is also expected to increase, resulting in hospital admissions and surgeries. Additionally, the increasing innovative launches by market players to meet the growing demand are also expected to boost the growth of the market. For instance, in March 2021, Medtronic launched the chameleon percutaneous transluminal angioplasty balloon catheter in the Europeann regions. However, high costs and the post-operational complications associated with angioplasty are expected to hamper the market growth.

Angioplasty Balloons Market Trends

Hospitals Segment is Expected to Dominate the Angioplasty Balloons Market Over the Forecast Period

The hospital segment is expected to hold a major share of the overall angioplasty balloons market. The factors responsible for the dominance of this segment are advanced healthcare infrastructure, increasing availability of skilled labor, and affordability. In addition, the substantial growth in the geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, is expected to increase the patient pool and enhance hospital revenue generation.

Moreover, compared to conventional surgeries, the several advantages of minimally invasive surgeries, such as reduced surgical pain, injury, scarring, hospital stay, higher accuracy, and speedy recovery time, encourage more patients to opt for minimally invasive balloon angioplasty surgeries. As per the data reported by the American College of Cardiology in 2020, approximately 1.2 million angioplasties are performed in a year in the United States. Moreover, the high accessibility and affordability of hospitals, as compared to specialty clinics, are expected to attract a large patient population.

However, due to the current COVID-19 situation, limited movement of the population in hospitals is being observed. Except for an emergency, people are keen to avoid undergoing surgery or diagnostic procedures to limit the risk of COVID-19 infection. In addition, hospitals have also transferred their personnel availability from cardiac departments to other departments in need, such as EDs or intensive care units (ICU). All these factors are expected to affect the market growth. Nevertheless, this slowdown in growth is anticipated to be temporary, and in the long run, the market is expected to have significant growth.

The graph below suggests that the burden of cardiovascular disease is continuously surging in developed regions, such as North America, owing to the change in lifestyle habits and the high burden of obesity among the population. This surge in disease prevalence is expected to boost the demand for the angioplasty balloons market.

North America is Expected to Hold a Significant Share in the Angioplasty Balloons Market Over the Forecast Period

North America accounted for the maximum revenue share in the angioplasty balloons market. The presence of key industry players, the rising healthcare expenditure, and the growing number of percutaneous coronary interventions are the primary drivers of the market in the region. According to the Centers for Disease and Prevention (CDC), in 2022, about 659,000 people in the United States die from heart disease each year which is one in every four deaths. Thus, there exists a higher demand for better treatment with advanced medical devices, which acts as a major factor driving the studied market.

In addition, the increasing product approvals by regulatory bodies in the United States are also expected to drive the market's growth. In November 2020, InfinityAngioplasty Balloon Co. announced its innovative angioplasty balloon platform called Infinity Angioplasty Balloon Catheter and completed a First-in-Human clinical trial. The device received the Food and Drug Administration's clearance for PTA treatment of peripheral arterial disease in the peripheral vasculature, including iliac, femoral, popliteal, and infra-popliteal arteries, and for the treatment of arteriovenous dialysis fistulae in June 2020. All these developments are further expected to increase the robust product line of the market and are anticipated to offer lucrative growth opportunities to the market of this region.

Angioplasty Balloons Market Competitor Analysis

The angioplasty balloons market is fragmented, with many prominent players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott laboratories, Angiodynamic, Becton Dickinson, Biotronik, Boston Scientific Corporation, Braun Melsungen AG, Cook Medical, Cordis, Endocor GmbH, Infinity Angioblast balloon, Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Merit Medical System, Inc, Oscor Inc, Terumo Corporation and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Cardiovascular Diseases
    • 4.2.2 Increasing Preference for Minimally Invasive Procedures and Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with the Procedure
    • 4.3.2 Complications Associated with Angioplasty Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Normal Balloons
    • 5.1.2 Cutting/Scoring Balloons
    • 5.1.3 Drug Eluting Balloons
  • 5.2 By Application
    • 5.2.1 Coronary Angioplasty
    • 5.2.2 Peripheral Angioplasty
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 AngioDynamics
    • 6.1.3 Becton Dickinson
    • 6.1.4 BIOTRONIK
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Braun Melsungen AG
    • 6.1.7 Cook Medical
    • 6.1.8 Cordis (Cardinal Health)
    • 6.1.9 Endocor GmbH
    • 6.1.10 INFINITY Angioplasty Balloon
    • 6.1.11 Johnson & Johnson
    • 6.1.12 Koninklijke Philips N.V.
    • 6.1.13 Medtronic Plc
    • 6.1.14 Merit Medical Systems, Inc.
    • 6.1.15 Oscor Inc.
    • 6.1.16 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS